As a weak acid, methotrexate (MTX) is bound to serum albumin and has variable protein binding. The purpose of this study was to assess serum albumin’s relationship with MTX pharmacokinetics by comparing MTX clearance and toxicities between patients with normal serum albumin to those with hypoalbuminemia. This single-center retrospective study included adult patients with leukemia or lymphoma who received their first MTX at a dose ≥1 g/m2. Hypoalbuminemia was defined as serum albumin ≤3.4 g/dL. MTX clearance was defined as the first documented time the MTX level ≤0.05 μM. Fisher’s exact tests and Wilcoxon rank sum tests were used to examine differences in toxicities, and Cox proportional hazard regression was used to assess relationship with time to clearance. Of 523 patients identified, 167 patients were evaluable. One hundred thirty-five patients had normal serum albumin and 32 had hypoalbuminemia. Hypoalbuminemia was associated with a higher proportion of patients experiencing edema, ascites or pleural effusions (34 vs. 12 %, p = 0.006), and the concomitant use of nephrotoxic agents (41 vs. 20 %, p = 0.021). Hypoalbuminemia was associated with a significantly longer time to MTX clearance (median 96 vs. 72 h, p = 0.004). In addition, patients with hypoalbuminemia had a higher proportion of hyperbilirubinemia and significantly longer hospitalization (median 14 vs. 5 days, p < 0.001). In conclusion, hypoalbuminemia was associated with increased time to MTX clearance and increased length of hospitalization. High dose MTX is safe to administer in patients with low albumin levels, with appropriate leucovorin rescue, and good supportive care.
Methotrexate Hypoalbuminemia Pharmacokinetics Toxicity Clearance Albumin Leukemia Lymphoma High dose methotrexate
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Jolivet J, Cowan KH, Curt GA et al (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094–1104CrossRefPubMedGoogle Scholar
Kantarjian HM, O’Brien S, Smith TL et al (2000) Results of treatment with hyper-CVAD, a dose intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547–561PubMedGoogle Scholar
Magrath I, Adde M, Venzon D et al (1996) Adults and children with small non-cleaved cell lymphoma have similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934PubMedGoogle Scholar
Mead GM, Sydes MR, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom lymphoma group LY06 study. Ann Oncol 13:1264–1274CrossRefPubMedGoogle Scholar
Yamaguchi M, Kwong YL, Kim WS et al (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol 29:4410–4416CrossRefPubMedGoogle Scholar
Paci A, Veal G, Bardin C, et al. (2014). Review of therapeutic drug monitoring of anticancer drugs part 1—cytotoxics. Eur J Cancer. 50:2010–2019Google Scholar
Stehle G, Sinn H, Wunder A, Schrenk HH, Schu¨Tt S, Heene DL, Maier-Borst W (1999) The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anticancer Drugs 8:677–685Google Scholar
Stehle G, Wunder A, Sinn H et al (1997) Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs 8:835–844CrossRefPubMedGoogle Scholar
Hartung G, Stehle G, Sinn H et al (1999) Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin Canc Res 5:753–759Google Scholar
Choi YH, Bae SK, Oh JM et al (2007) Pharmacokinetics of intravenous methotrexate in mutant Nagase analbuminemic rats. Biopharm Drug Dispos 28:385–392CrossRefPubMedGoogle Scholar
Alarcon GS, Kremer JM, Macaluso M et al (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. Ann Intern Med 127:356–364CrossRefPubMedGoogle Scholar
Wiczer T, Dotson E, Tuten A et al (2016) Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract 22:430–436CrossRefPubMedGoogle Scholar
Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23:68–72CrossRefPubMedGoogle Scholar
Finfer S, Bellomo R, Boyce N et al (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350:2247–2256CrossRefPubMedGoogle Scholar
The Official Statement of the American Thoracic Society (2004) Evidence-based colloid use in the critically Ill: American thoracic society consensus statement. Am J Respir Crit Care Med 170:1247–1259CrossRefGoogle Scholar
Guthrie RD Jr, Hines C Jr (1991) Use of intravenous albumin the critically ill patient. Am J Gastroenterol 86:255–263PubMedGoogle Scholar
Kettle JK, Grauer D, Folker TL et al (2010) Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy 30:812–817CrossRefPubMedGoogle Scholar